Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03998319
Other study ID # CTC0150
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date October 14, 2021
Est. completion date December 31, 2026

Study information

Verified date October 2023
Source University of Sydney
Contact Martin Ng, MBBS (Hons)
Phone +614 3407 8507
Email martin.ng@sydney.edu.au
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Heart attacks are caused by a blood clot blocking the blood vessels of the heart, preventing blood getting to the heart muscle. Opening up the artery with a balloon (angioplasty) and a small mesh tube (stent) although life saving can cause this clot to break up and get washed downstream, which can make the heart attack worse. The investigators can measure the amount of damage caused to the microcirculation by calculating the IMR (Index of Microcirculatory resistance). This can be measured by a wire in the coronary artery with a pressure sensor at the tip. If the IMR is elevated, it is suggestive of extensive microcirculatory damage. A clot dissolving medicine can be administered in the artery to try and reduce the IMR which can reduce damage to the heart muscle and improve outcomes. Impaired microcirculatory perfusion in patients as a result of ST-elevation myocardial infarction (STEMI) is associated with poor clinical outcomes. This project seeks to identify patients with impaired microcirculatory perfusion after STEMI and to assess whether acute improvement in microcirculatory perfusion in these patients by the use of intracoronary thrombolytic therapy results in improved clinical outcomes.


Description:

Patients presenting to the participating hospitals with a heart attack will be approached to participate in the study. After angioplasty has been performed, the IMR will be measured in the infarct related artery. If the IMR is >32 patients will be randomised to receive intracoronary clot dissolving therapy in the form of low dose tenecteplase (TNK) or water as a placebo. Patients who have an IMR ≤32 will be followed up in a registry. Cardiac enzymes will be measured at baseline and discharge. Randomised participants will receive a cardiac MRI at discharge (3-7 days post primary PCI) and at 6 months post PCI. All participants will be followed up at 30 days, and 6, 12 and 24 months following discharge.


Recruitment information / eligibility

Status Recruiting
Enrollment 445
Est. completion date December 31, 2026
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adult men and women aged over 18 who present with STEMI within 6 hours of symptom onset. Patients will be eligible if they have symptoms consistent with myocardial ischaemia (chest pain, dyspnoea) for at least 20 minutes accompanied by definite ECGs indicating STEMI as defined by Australian National Heart Foundation (NHF) guidelines 2. Willing and able to comply with all study requirements, including treatment, assessment and clinic visit attendances 3. Able to personally read and understand the Participant Information and Consent Form and provide written, signed and dated informed consent to participate in the study 4. (At time of PCI) Patient has received metallic drug-eluting stent 5. Participant consents to have a 3-7 day (discharge) and 5 month follow up cardiac MRI Exclusion Criteria: At the time of screening and/or prior to randomisation, no known; 1. Previous coronary bypass grafting 2. Other residual lesions with =50% diameter stenosis in the culprit vessel 3. Prior myocardial infarction in the target territory 4. Presence of contraindications to thrombolytic therapy (including history of stroke and recent brain surgery active internal bleeding; history of cerebrovascular accident; intracranial or intraspinal surgery, or trauma within 2 months; intracranial neoplasm, arteriovenous malformation, or aneurysm; known bleeding diathesis; and severe uncontrolled hypertension) 5. Presence of contraindications to adenosine infusion for IMR measurement including sinus node disease, moderate to severe bronchoconstrictive disease and second or third-degree atrioventricular (AV) block 6. Diagnosis of metastatic disease 7. Concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety 8. Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol 9. Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal, infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration. Men must have been surgically sterilised or use a (double if required) barrier method of contraception. 10. Participation in any investigational study in the previous 30 days Other exclusion criteria: 11. (Cardiac MRI cohort only) Presence of contraindications to contrast enhanced MRI including severe claustrophobia, pregnancy, pacemakers, non-MRI compatible aneurysm clips, defibrillators and estimated glomerular filtration rate of <30mL/min. (At time of PCI) 12. Patients who received GpIIb/IIIa treatment prior to IMR measurement 13. Patients who do not undergo primary PCI due to lack of severity of culprit lesion or other reasons.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tenecteplase (1/3 systemic weight based dose)
50mg reconstituted to 20mL for intracoronary infusion at 1/3 weight based dose.
Other:
Sterile water for injection (WFI)
Placebo comparative arm.

Locations

Country Name City State
Australia Royal Adelaide Hospital Adelaide South Australia
Australia Bankstown-Lidcombe Hospital Bankstown New South Wales
Australia Box Hill Hospital Box Hill Victoria
Australia Royal Prince Alfred Hospital Camperdown New South Wales
Australia Jessie McPherson Private Hospital Clayton Victoria
Australia Monash Medical Centre - Clayton Clayton Victoria
Australia Concord Repatriation General Hospital Concord New South Wales
Australia Lyell McEwin Hospital Elizabeth Vale South Australia
Australia The Northern Hospital Epping Victoria
Australia Frankston Hospital Frankston Victoria
Australia Northern Beaches Hospital Frenchs Forest New South Wales
Australia Liverpool Hospital Liverpool New South Wales
Australia Fiona Stanley Hospital Murdoch Western Australia
Australia John Hunter Hospital New Lambton Heights New South Wales
Australia Royal Perth Hospital Perth Western Australia
Australia Prince of Wales Hospital Randwick New South Wales
Australia Sunshine Hospital Saint Albans Victoria
Australia Wollongong Hospital Wollongong New South Wales
New Zealand Auckland City Hospital Auckland
New Zealand Christchurch Hospital Christchurch
New Zealand Waikato Hospital Hamilton
New Zealand Wellington Hospital Wellington

Sponsors (1)

Lead Sponsor Collaborator
University of Sydney

Countries where clinical trial is conducted

Australia,  New Zealand, 

Outcome

Type Measure Description Time frame Safety issue
Other DNA analyses (Subject to funding) Samples of whole blood will be used for DNA analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). 0-6 months
Other MicroRNA analyses (Subject to funding) Samples of whole blood will be used for microRNA analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). 0-6 months
Other Vasoactive markers (Subject to funding) Samples of whole blood will be used for vasoactive marker analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). 0-6 months
Other Inflammatory markers (Subject to funding) Samples of whole blood will be used for inflammatory marker analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). 0-6 months
Other Angiogenic markers (Subject to funding) Samples of whole blood will be used for angiogenic marker analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). 0-6 months
Other Liver function (Subject to funding) Samples of whole blood will be used for liver function analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). 0-6 months
Other Thyroid Function (Subject to funding) Samples of whole blood will be used for thyroid function analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). 0-6 months
Other Lipid profile (Subject to funding) Samples of whole blood will be used for lipid profile analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). 0-6 months
Other Lipoprotein profile (Subject to funding) Samples of whole blood will be used for lipoprotein profile analyses at baseline, post-PCI, discharge and 6 month follow up (6m follow up for Randomised participants only). 0-6 months
Primary To compare the number of participants who experience cardiovascular mortality and rehospitalisation for heart failure at 24 months in those given tenecteplase with those given placebo (Cardiac MRI cohort only) Cardiovascular mortality and rehospitalisation for heart failure assessed by medical record review. 24 months
Primary To compare MI size as a % of LV mass and intramyocardial bleeding rates in participants at 6 months post PCI in those given low dose tenecteplase with those given placebo. MI size and intramyocardial bleeding rates will be assessed upon cardiac MRI at discharge (3-7 days post procedure) as a baseline measure, and at 6 months post-PCI. 6 months after primary PCI procedure.
Secondary Number of participants who experience individual components of the primary endpoint: (a) cardiovascular mortality at 24 months, (b) rehospitalisation for heart failure at 24 months; Cardiovascular mortality and rehospitalisation for heart failure assessed by medical record review, respectively. 24 months after primary PCI procedure
Secondary Number of Major Adverse Cardiac Events (MACE) Major Adverse Coronary Events (these are combination events involving cardiovascular death, non-fatal MI, non-fatal stroke and unstable angina) assessed from physical assessment and medical record review 24 months after primary PCI procedure
Secondary All-cause mortality All-cause mortality assessed by physical assessment and medical record review. 24 months after primary PCI procedure
Secondary Number of stroke events Stroke events will be assessed by medical record review. Assessment will cover all aspects of the stroke event (including type, severity, frequency). 24 months after primary PCI procedure
Secondary Number of incidences of bailout treatment use for no-reflow syndrome Use of Bailout treatment for no-reflow syndrome assessed by medical record review 24 months after primary PCI procedure
Secondary Occurrence of major (Type 3 or greater) and minor (Type 2) bleeding as defined by the Bleeding Academic Research Consortium Major (Type 3 or greater) and minor (Type 2) bleeding as defined by the Bleeding Academic Research Consortium. Assessed by medical record review. 24 months after primary PCI procedure
Secondary Index of Microcirculatory Resistance (IMR) Index of microcirculatory resistance (IMR) measurement assessed by coronary pressure wire data output review.
This is a simple unit scale, with a higher number indicating a worse outcome with a score of more than 25 indicating abnormal microcirculatory function in the heart.
0-2 hours
Secondary Fractional Flow Reserve (FFR) Fractional Flow Reserve measurement assessed by coronary pressure wire data output review prior to randomisation and immediately after primary PCI 0-2 hours
Secondary Coronary Flow Reserve (CFR) Coronary Flow Reserve measurement assessed by coronary pressure wire data output review, prior to randomisation and immediately after primary PCI. 0-2 hours
Secondary Wall Motion Score The score is measured by simple unit scale (1 = normal, 2 = hypokinetic (muscle impaired), 3= akinetic (muscle dead)). Each of the 16 segments of the hearts is scored, with the total being divided by 16 to derive the score. 0-6 months
Secondary Left ventricular ejection fraction (LVEF) Left ventricular ejection fraction measurement from echocardiogram will be used to assess cardiac function prior to randomisation, 48 hours and 6 months post primary PCI 0-6 months
Secondary Myocardial Blush Grade Myocardial Blush Grade measurement from angiogram will be used to assess cardiac function. The score goes from 0 to 3, with 3 being normal and 0 being absence of myocardial blush 0-2 hours
Secondary TIMI Myocardial Perfusion Grade Thrombolysis in myocardial infarction score from angiogram will be used to assess myocardial perfusion. This score goes from 0 to 3, 3 indicates normal flow within the artery and 0 indicates a complete coronary occlusion. 0-2 hours
Secondary TIMI corrected frame count Thrombolysis in myocardial infarction score with corrected frame count from angiogram to assess myocardial perfusion 0-2 hours
Secondary Cardiac enzyme measurements Cardiac enzyme levels including troponin T, creatine kinase, creatine kinase-MB and high sensitivity troponin T, from blood samples collected during the hospitalisation period (prior to primary PCI and at 8, 16, 24 and 32 hours post primary PCI). 0-32 hours
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Completed NCT01452139 - Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI) Phase 2/Phase 3
Completed NCT01325116 - Delayed Educational Reminders in Acute Myocardial Infarction (MI) N/A
Completed NCT01625104 - Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI N/A
Completed NCT04023266 - A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI Phase 2
Completed NCT02170103 - Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial N/A
Completed NCT03103620 - Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
Not yet recruiting NCT05975567 - Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
Enrolling by invitation NCT03328156 - Erectile Dysfunction After Percutaneous Coronary Intervention Versus the Thrombolytic Therapy in Acute ST Elevation Myocardial Infarction N/A
Completed NCT04017169 - No Reflow Phenomenon Incidence and Predictors
Completed NCT03470441 - A Study of Acute Myocardial Infarction Using FDY-5301 Phase 2
Active, not recruiting NCT01433627 - Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX Phase 3
Completed NCT01197742 - Sweetheart-Register: Risk Management of Diabetics With Acute Myocardial Infarction N/A
Terminated NCT03439150 - Resistance STEMI Study N/A
Not yet recruiting NCT05974930 - Intravascular ULTRAsound-Guided PCI in Patients With ST-Elevation Myocardial Infarction
Active, not recruiting NCT03102723 - Platelet Inhibition to Target Reperfusion Injury Phase 2
Completed NCT03930589 - Remote Ischemic Conditioning in STEMI to Decrease Infarct Size N/A
Not yet recruiting NCT04912167 - The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction Phase 3
Completed NCT02942550 - Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients Phase 4
Recruiting NCT02604394 - Rheolytic Thrombectomy in Patients With Acute STEMI and Large Thrombus Burden N/A